Literature DB >> 16935688

Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study.

Ian P Hall1, John D Blakey, Khalid A Al Balushi, Amanda Wheatley, Ian Sayers, Marcus E Pembrey, Susan M Ring, Wendy L McArdle, David P Strachan.   

Abstract

BACKGROUND: Functionally relevant polymorphisms of the beta2-adrenoceptor gene (ADRB2) are common in white populations, but their contribution to the burden of airways disease in the population is uncertain. We aimed to relate the long-term prevalence of asthma or wheeze to functional coding region polymorphisms in the ADRB2 gene.
METHODS: The British 1958 birth cohort consisted of all people born in Britain during a week in 1958. Asthma, wheezy bronchitis, and wheezing were ascertained by interview at ages 7, 11, 16, 23, 33, and 42 years, and lung function tests at 35 and 45 years. DNA samples from 8018 participants in the 45-year follow-up were genotyped for three coding variants in the ADRB2 gene. We extend the follow-up of this nationwide cohort by a further 10 years and relate asthma prevalence, prognosis, and lung function to functional coding region polymorphisms in the ADRB2 gene in the cohort members who contributed DNA samples. We also compared and combined our findings with those reaching significance in two previous meta-analyses.
FINDINGS: Half the cohort (4105 of 8018) had some history of wheezing illness by age 42 years. Neither lifetime prevalence nor age at onset were related to ADRB2 coding variants. However, the common polymorphisms Arg16Gly (rs1042713, Arg 16 allele frequency 36.3%) and Gln27Glu (rs1042714, Glu 27 allele frequency 44.6%) were significantly associated with persistence of asthmatic symptoms from childhood to middle age. Among homozygotes for the Arg16-Gln27 haplotype at these loci, 19.3% (41 of 212) childhood wheezers had five or more wheezing episodes in the past year at age 42, compared with 11.9% (71 of 599) with no copy of this haplotype. However, only 3% of all frequent adult wheezing was statistically attributable to this haplotype. The less common Thr164Ile polymorphism (rs1800888, Ile allele frequency 1.5%) was not a major predictor of either frequency or prognosis of asthma. Our data do not support the findings of previous meta-analyses when considered in isolation or when combined with their contributory studies.
INTERPRETATION: ADRB2 polymorphisms might predict a small component of the long-term prognosis in childhood asthma, but are not important determinants of asthma incidence or prevalence in the British population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935688     DOI: 10.1016/S0140-6736(06)69287-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

1.  Looking for a bit of co-action?

Authors:  John D Blakey
Journal:  Thorax       Date:  2007-03       Impact factor: 9.139

Review 2.  β2 Agonists.

Authors:  Charlotte K Billington; Raymond B Penn; Ian P Hall
Journal:  Handb Exp Pharmacol       Date:  2017

3.  Methacholine PC20 in African Americans and whites with asthma with homozygous genotypes at ADRB2 codon 16.

Authors:  Kathryn Blake; James D Cury; Jobayer Hossain; Kelan Tantisira; Jianwei Wang; Edward Mougey; John Lima
Journal:  Pulm Pharmacol Ther       Date:  2013-02-04       Impact factor: 3.410

Review 4.  Pharmacogenetics of asthma.

Authors:  John J Lima; Kathryn V Blake; Kelan G Tantisira; Scott T Weiss
Journal:  Curr Opin Pulm Med       Date:  2009-01       Impact factor: 3.155

Review 5.  Pharmacogenetics of the beta 2-adrenergic receptor gene.

Authors:  Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker
Journal:  Immunol Allergy Clin North Am       Date:  2007-11       Impact factor: 3.479

6.  GPCRs and arrestins in airways: implications for asthma.

Authors:  Raymond B Penn; Richard A Bond; Julia K L Walker
Journal:  Handb Exp Pharmacol       Date:  2014

7.  Variable-length poly-C tract polymorphisms of the beta2-adrenergic receptor 3'-UTR alter expression and agonist regulation.

Authors:  Alfredo Panebra; Mary Rose Schwarb; Steven M Swift; Scott T Weiss; Eugene R Bleecker; Gregory A Hawkins; Stephen B Liggett
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-11-16       Impact factor: 5.464

8.  Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases.

Authors:  John D Rioux; Philippe Goyette; Timothy J Vyse; Lennart Hammarström; Michelle M A Fernando; Todd Green; Philip L De Jager; Sylvain Foisy; Joanne Wang; Paul I W de Bakker; Stephen Leslie; Gilean McVean; Leonid Padyukov; Lars Alfredsson; Vito Annese; David A Hafler; Qiang Pan-Hammarström; Ritva Matell; Stephen J Sawcer; Alastair D Compston; Bruce A C Cree; Daniel B Mirel; Mark J Daly; Tim W Behrens; Lars Klareskog; Peter K Gregersen; Jorge R Oksenberg; Stephen L Hauser
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-21       Impact factor: 11.205

9.  Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.

Authors:  I Sayers; J Hawley; C E Stewart; C K Billington; A Henry; J R Leighton-Davies; S J Charlton; I P Hall
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

10.  Adverse effects of salmeterol in asthma: a neuronal perspective.

Authors:  M Lommatzsch; Y Lindner; A Edner; K Bratke; M Kuepper; J C Virchow
Journal:  Thorax       Date:  2009-02-22       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.